PRECIGEN INC PGEN 深 滬
已收盤 12-19 16:00:00 美东时间
4.32
+0.150
+3.60%
華盛通- 最 高4.525
- 今 開4.22
- 成交量 2304.21万股
- 最 低 4.12
- 昨 收 4.17
- 總市值 15.29亿
- 52周最高 5.225
- 市盈率 靜 --
- 換手率 6.51%
- 52周最低 0.7555
- 委 比 -44.73%
- 總股本 3.54亿
- 歷史最高 69.2096
- 量 比 3.96
- 振 幅 9.71%
- 歷史最低 0.6513
- 每 手 1
- 風險率 1.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Precigen’s Optimistic Earnings Call Highlights Papcemias Success
Precigen, Inc. (($PGEN)) has held its Q3 earnings call. Read on for the main hi...
11-15 08:28
Vaxart, Precigen among biotech gainers after Q3 results
Shares of oral vaccine developer Vaxart (OTC:VXRT) and immunotherapy maker Precigen (PGEN) surged on Friday after the two biotechs posted strong topline beats with their Q3 2025 financials. San Franci...
11-15 03:06
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $9
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price target from $8.5 to $9.
11-14 21:00
Precigen Q3 EPS $(1.06) Misses $(0.10) Estimate, Sales $2.922M Beat $500.000K Estimate
Precigen (NASDAQ:PGEN) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.10) by 1015.79 percent. This is a 1077.78 percent decrease over losses of $(0.09) per share from
11-14 05:12
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
Inovio outlines mid-2026 launch for INO-3107 as BLA submission progresses
Earnings Call Insights: Inovio Pharmaceuticals (INO) Q3 2025 Management View CEO Jacqueline Shea highlighted, “we have achieved our primary objective for this year, which is completing the rolling sub...
11-11 08:32
Precigen Reports Responses to PAPZIMEOS in Adults With Recurrent Respiratory Papillomatosis, Reinforcing FDA Approval
Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced long-term follow-up data demonstrating durable
10-13 19:12
Precigen Converts Preferred Stock to Common Shares
An announcement from Precigen ( ($PGEN) ) is now available. On September 15, 20...
09-18 05:18
Precigen announces up to $125M non-dilutive financing
Precigen (NASDAQ:PGEN) said on Wednesday that it has entered into a credit facility agreement with investment funds managed by Pharmakon Advisors. The credit facility provides Precigen with up to $12...
09-03 19:45
